Terms: = Kidney tumors AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Diagnosis
66 results:
1. Calyceal diverticulum simulating a renal tumor.
Fernandez-Alberti J; Coronil R; Iotti A; Nolazco A; Featherston M
Can J Urol; 2023 Aug; 30(4):11629-11632. PubMed ID: 37633292
[TBL] [Abstract] [Full Text] [Related]
2. Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors.
Oppolzer IA; Riester J; Büttner R; Burger M; Schnabel MJ
Int Urol Nephrol; 2023 Aug; 55(8):1943-1949. PubMed ID: 37271776
[TBL] [Abstract] [Full Text] [Related]
3. Construction of a prognostic prediction model for renal clear cell carcinoma combining clinical traits.
Weng Y; Ning P
Sci Rep; 2023 Feb; 13(1):3358. PubMed ID: 36849551
[TBL] [Abstract] [Full Text] [Related]
4. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors.
Chennamadhavuni A; Abushahin L; Jin N; Presley CJ; Manne A
Front Immunol; 2022; 13():779691. PubMed ID: 35558065
[TBL] [Abstract] [Full Text] [Related]
5. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States.
Jain P; Gutierrez Bugarin J; Guha A; Jain C; Patil N; Shen T; Stanevich I; Nikore V; Margolin K; Ernstoff M; Velcheti V; Barnholtz-Sloan J; Dowlati A
ESMO Open; 2021 Oct; 6(5):100252. PubMed ID: 34461483
[TBL] [Abstract] [Full Text] [Related]
6.
Klümper N; Ralser DJ; Zarbl R; Schlack K; Schrader AJ; Rehlinghaus M; Hoffmann MJ; Niegisch G; Uhlig A; Trojan L; Steinestel J; Steinestel K; Wirtz RM; Sikic D; Eckstein M; Kristiansen G; Toma M; Hölzel M; Ritter M; Strieth S; Ellinger J; Dietrich D
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446578
[TBL] [Abstract] [Full Text] [Related]
7. Inflammatory pseudotumor of Castleman disease and IgG4-related disease masquerading as kidney malignancy.
Liu B; Huang Y; Tang L; Guan J; Zhou X; Zhan H
Diagn Pathol; 2021 Aug; 16(1):74. PubMed ID: 34376196
[TBL] [Abstract] [Full Text] [Related]
8. Sporadic hemangioblastoma of the kidney: a clinicopathologic study of three cases and a literature review.
Xu Y; Ma X; Ma Y; Li J; Zhang R; Li X
J Int Med Res; 2021 Jul; 49(7):3000605211027774. PubMed ID: 34256639
[TBL] [Abstract] [Full Text] [Related]
9. [kidney injury associated with antitumor therapy: focus on the adverse events of modern immuno-oncological drugs].
Kamyshova ES; Bobkova IN; Sekacheva MI
Ter Arkh; 2021 Jun; 93(6):649-660. PubMed ID: 36286830
[TBL] [Abstract] [Full Text] [Related]
10. Immune checkpoint inhibitor-associated hypercalcaemia.
Izzedine H; Chazal T; Wanchoo R; Jhaveri KD
Nephrol Dial Transplant; 2022 Aug; 37(9):1598-1608. PubMed ID: 33374000
[TBL] [Abstract] [Full Text] [Related]
11. TYROBP is a potential prognostic biomarker of clear cell renal cell carcinoma.
Wu P; Xiang T; Wang J; Lv R; Wu G
FEBS Open Bio; 2020 Dec; 10(12):2588-2604. PubMed ID: 33015999
[TBL] [Abstract] [Full Text] [Related]
12. Diagnostic utility of amylase α-1A, MOC 31, and
Abouhashem NS; Abdelbary EH; H Abdalla MM; El-Shazly M
Indian J Pathol Microbiol; 2020; 63(3):405-411. PubMed ID: 32769329
[TBL] [Abstract] [Full Text] [Related]
13. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes.
Meraz-Muñoz A; Amir E; Ng P; Avila-Casado C; Ragobar C; Chan C; Kim J; Wald R; Kitchlu A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32601079
[TBL] [Abstract] [Full Text] [Related]
14. Management of Immunotherapy Adverse Events in Oncological Patients: Anti-ctla-4, Anti-PD-1/PD-L1.
Brigida M; Perricelli A; Sposato F; Spadafora MG; Pomillo A; Sisto M
Rev Recent Clin Trials; 2020; 15(4):339-346. PubMed ID: 32568023
[TBL] [Abstract] [Full Text] [Related]
15. [What is new in the diagnosis and therapy of renal cell carcinoma?].
Ahrens M; Hartmann A; Bergmann L
Dtsch Med Wochenschr; 2020 Jun; 145(11):734-739. PubMed ID: 32492742
[TBL] [Abstract] [Full Text] [Related]
16. Small Cell Carcinoma of Bladder; Still A Diagnostic and Therapeutic Challenge: Seven Years of Experience and Follow-up in A Referral Center.
Kaffash Nayeri R; Sadri M; Shahrokh H; Abolhasani M; Khaleghimehr F; Zolfi E; Yousefzadeh Kandevani N; Kashi AH
Urol J; 2020 Jun; 17(4):363-369. PubMed ID: 32309874
[TBL] [Abstract] [Full Text] [Related]
17. [Renal Cancer Tissue after Nivolumab/Ipilimumab Combination Therapy for Metastatic Renal Cell Carcinoma].
Okuno Y; Tanaka R; Mikami K; Takeuchi T
Hinyokika Kiyo; 2020 Jan; 66(1):13-17. PubMed ID: 32028750
[TBL] [Abstract] [Full Text] [Related]
18. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
Thapi S; Leiter A; Galsky M; Gallagher EJ
J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
[TBL] [Abstract] [Full Text] [Related]
19. Multiple sclerosis outcomes after cancer immunotherapy.
Garcia CR; Jayswal R; Adams V; Anthony LB; Villano JL
Clin Transl Oncol; 2019 Oct; 21(10):1336-1342. PubMed ID: 30788836
[TBL] [Abstract] [Full Text] [Related]
20. Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients.
Zehou O; Leibler C; Arnault JP; Sayegh J; Montaudié H; Rémy P; Glotz D; Cordonnier C; Martin L; Lebbé C
Am J Transplant; 2018 Dec; 18(12):3065-3071. PubMed ID: 30107088
[TBL] [Abstract] [Full Text] [Related]
[Next]
